Breast Cancer Research and Treatment

, Volume 55, Issue 3, pp 203–211 | Cite as

Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony‐stimulating factor

  • Karin Haider
  • Gabriela V. Kornek
  • Werner Kwasny
  • Georg Weinländer
  • Julia Valencak
  • Friedrich Lang
  • F. Püribauer
  • Erwin Kovats
  • Dieter Depisch
  • Werner Scheithauer


Purpose. A phase II trial was performed to investigate the efficacy and tolerance of gemcitabine, vinorelbine, and recombinant human granulocyte colony‐stimulating factor (G‐CSF) in advanced breast cancer.

Patients and methods. Between April 96 and August 97, 60 patients entered this trial. Forty‐five patients were previously untreated and 15 patients had failed previous palliative chemotherapy with (n = 10) or without anthracyclines (n = 5). Therapy consisted of gemcitabine 1000 mg/m2 on days 1 + 15 + 21 and vinorelbine 40 mg/m2 on days 1 + 21, both diluted in 250 ml saline and infused over 30 min. G‐CSF was administered at 5 μg/kg/day subcutaneously from days 2–6 and 22–26. Courses were repeated every 5 weeks. Treatment was continued in case of response or stable disease until a total of six courses.

Results. The overall response rate was 55.5% for patients who had not received prior palliative chemotherapy (95% confidence interval, 40%–70.3%), including 5 CR (11.1%) and 20 PR (44.4%) 12 patients (27%) had stable disease (SD), and 8 (18%) progressed. Second‐line treatment with this regimen resulted in 6/15 (40%) objective remissions, 5 had SD, and 4 PD. The median time to progression was 9.5 months (range, 1.5–28) in previously untreated patients, and 7.0 months (range, 2–23) in those who had failed prior chemotherapy. After a median follow‐up time of 15 months, 44 patients (73%) are still alive with metastatic disease. Myelosuppression was commonly observed, though WHO 3 and 4 neutropenia occured in only 9 (l5%) and 2 patients (3%), and was never complicated by septicaemia; grade 3 anemia was noted in 2 patients. Severe (WHO grade 3) nonhematologic toxicity was rarely observed, and included nausea/emesis in 3 and constipation in 2 patients.

Conclusions. Our data suggest that gemcitabine and vinorelbine plus G‐CSF is an effective and tolerable first‐ as well as second‐line combination regimen for treatment of advanced breast cancer.

advanced breast cancer chemotherapy gemcitabine vinorelbine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bonadonna G, Vallagussa P, Moliterni A, Zambanetti M, Brambilla C: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node positive breast cancer: The results of 20 years follow-up. New Engl J Med 14: 332-341, 1995Google Scholar
  2. 2.
    Valagussa P, Bonadonna G, Veronesi A, Harvey H, Hutchins L, Bigley J, Hohneker J: Patterns of relapse and survival following radical mestectomy. Cancer 41: 1170-72, 1978Google Scholar
  3. 3.
    Carmichel J, Walling J: Advanced breast cancer: Investigational role of gemcitabine. Eur J Cancer 33(suppl 1): S27-S30, 1997Google Scholar
  4. 4.
    Arning M, Blatter J: Gemcitabine in solid tumors — present status and further development. Onkologie 20: 297-304, 1997Google Scholar
  5. 5.
    Budman DR: Vinorelbine (Navelbine): A third-generation vinca alkaloid. Cancer Invest 15: 475-490, 1997Google Scholar
  6. 6.
    Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB: Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50: 4417-4422, 1990Google Scholar
  7. 7.
    Binet S, Chaineau E, Fellous A, Cataste H, Krikorian A, Cozuzinier JP, Meininger V: Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic axonal microtubules. Int J Cancer 46: 262-266, 1990Google Scholar
  8. 8.
    Cannobio L, Boccardo F, Pastorino G, Brema F, Martini C, Resasco M, Santi L: Phase II study of navelbine in advanced breast cancer. Semin Oncol 16(suppl 4): 33-36, 1989Google Scholar
  9. 9.
    Fumoleau P, Delegado FM, Delozier T, Monnier A, Gil Delegado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT, Goudier MJ, Chollet P, Lecourt L, Montcuquet P: Phase II trial of weekly intravenous vinorelbine in first line advanced breast cancer chemotherapy. J Clin Oncol 11: 1245-1252, 1993Google Scholar
  10. 10.
    Garcia-Conde J, Lluch A, Martin M, Casado A, Gervasio H, De Oliveira C, De Pablo JL, Gorostiaga J, Giron GG, Cervantes A, Martinez A, Pezous N, Delegado FM, Diaz Rubio E: Phase II trial of weekly i.v. vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 5: 854-857, 1994Google Scholar
  11. 11.
    Bruno S, Puerto L, Mickiewicz E, Hegg R, Texeira LC, Gaitan L, Martinez L, Fernandez O, Otero J, Kesselring G: Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer. Am J Clin Oncol 18: 392-396, 1995Google Scholar
  12. 12.
    Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA, Machiavelli M, Lacava JA, Langhi M, Acuna LR, Amato S, Barbieri R, Sabatini C, Leone BA: Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12: 336-341, 1994Google Scholar
  13. 13.
    Marty M, Leandri S, Extra JM, Espie M, Besenval M: A phase II study of vinorelbine in patients with advanced breast cancer. Proc Am Assoc Cancer Res 30: 256, 1989 (abstr)Google Scholar
  14. 14.
    Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, Ambrosini G: Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: A phase II study. J Clin Oncol 12: 2094-2101, 1994Google Scholar
  15. 15.
    Degardin M, Bonneterre J, Hecquet B, Pion IM, Adenis A, Horner D, Demaille A: Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5: 424-426, 1994Google Scholar
  16. 16.
    Toussaint C, Izzo I, Spielman M, Merle S, May-Levin F, Armand JP, Lacombe D, Tursz T, Sunderland M, Chabot GG, Cvitkoviv E: Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. J Clin Oncol 12: 2102-2112, 1994Google Scholar
  17. 17.
    Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Hohneker J: Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. I Clin Oncol 13: 2722-2730, 1995Google Scholar
  18. 18.
    Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, Lembersky B, Budinan D, Bigley J, Hohneker J: Randomized comparison of vinorelbine and meiphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13: 2567-2574, 1995Google Scholar
  19. 19.
    Livingston RB, Ellis GK, Gralow IR, Williams MA, White R, McGuirt C, Adamkiewicz BB, Long CA: Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 15: 1395-1400, 1997Google Scholar
  20. 20.
    Ibrahim NK, Willey J, Rahman Z, Valero V, Hortobagyi GN: Phase II study of vinorelbine (VNR) by 96-hour (H) continuous infusion (CI) for patients (PTS) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 17: 113a, 1998 (abstr)Google Scholar
  21. 21.
    Conti F, Vici P: Vinorelbine in the treatment of breast cancer: Current status and prospectives for the future. Clin Ter 149: 61-74, 1998Google Scholar
  22. 22.
    Herbst R, Dang N, Lynch C, Teicher B, Strauss G, Elias A, Anderson I, Salgia R, Jacobs C, Skarin A: Phase I study of combination weekly gemcitabine and vinorelbine in patients with lung cancer. Proc Am Soc Clin Oncol 17: 488a, 1998 (abstr)Google Scholar
  23. 23.
    Miller AB, Hoogstraten B, Staquet M: Reporting results of cancer treatment. Cancer 147: 207-214, 1981Google Scholar
  24. 24.
    Gehan EA: The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chron Dis 13: 346-353, 1961Google Scholar
  25. 25.
    Anderson IR, Bernstein L, Pike MC: Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis. Biometrics 38: 407-416, 1982Google Scholar
  26. 26.
    Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 458-481, 1958Google Scholar
  27. 27.
    Hayes DF, Henderson IC: CAF in metastatic breast cancers: Standard therapy or another effective regimen? J Clin Oncol 5: 1497-1499, 1987Google Scholar
  28. 28.
    Hayes DF, Henderson C, Schapiro CL: Treatment of metastatic breast cancer: Present and future aspects. Semin Oncol 22(suppl 5): 5-21, 1995Google Scholar
  29. 29.
    Ayash LJ, Elias A, Wheeler C, Reich E, Schwartz G, Mazanet R, Tepler I, Warren D, Gonin R, Schnipper L, Frei E, Antman K: Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor support for metastatic breast cancer: A feasibility study. J Clin Oncol 12: 37-44, 1994Google Scholar
  30. 30.
    Spielmann M, Dorvalt T, Turpin F, Antoine E, Jouve M, Maylevin F, Lacombe D, Rousse J, Pouillart P, Tursz T, Merle S: Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 12: 1764-1770, 1994Google Scholar
  31. 31.
    Fabi A, Tonachella R, Savarese A, Cirulli S, Tomao S, Conte E, Cognetti F: A phase II trial of vinorelbine and thiotepa in metastatic breast cancer. Ann Oncol 6: 187-189, 1995Google Scholar
  32. 32.
    Scheithauer W, Kornek GV, Haider K, Kwasny W, Raderer M, Tueni C, Koperna-Mach K, Depisch D: Effective second-line chemotherapy for advanced breast cancer with navelbine and mitomycin C. Breast Cancer Res Treat 26: 49-53, 1993Google Scholar
  33. 33.
    Kornek GV, Haider K, Kwasny W, Hejna M, Raderer M, Meghdadi S, Burger D, Schneeweiss B, Depisch D, Scheithauer W: Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor. Br J Cancer 74: 1668-1673, 1996Google Scholar
  34. 34.
    Galvez C, Bonamassa MM, Ares S: A phase II trial of the use of docetaxel (D), vinorelbine (VNB) in combination with GM-CSF in taxol refractory metastatic breast cancer. Breast Cancer Res Treat 46: 95, 1997 (abstr)Google Scholar
  35. 35.
    Kornek GV, Haider K, Kwasny W, Lang F, Krauss G, Hejna M, Raderer M, Weinlaender G, Depisch D, Scheithauer W: Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and 1-leucovorin plus human granulocyte colony-stimulating factor. Br J Cancer 78: 673-678, 1998Google Scholar
  36. 36.
    Norris B, Pritchard K, James K, Myles J, Bennett K, Marlin S, Skillings J, Findlay B, Goss P, Latreille J, Lopez P, Osoba D, Rodgers A: A phase III comparative study of vinorelbine (VNB) combined with doxorubicin (DOX) versus doxorubicin alone in metastatic recurrent breast cancer (MIBC): A National Cancer Institute of Canada (NCI CTG) study. Proc Am Soc Clin Oncol 15: 98, 1996 (abstr)Google Scholar
  37. 37.
    Garcia-Conde J, Lluch A, Perez-Manga G, Palomero I, Alba E, Rueda A, Moreno-Noguiera JA, Calvo E, Tarazona Y, Lopez-Martin E: Gemcitabine + doxorubicin in advanced breast cancer: Final results from an early phase II study. Proc Am Soc Clin Oncol 16: 147a, 1997 (abstr)Google Scholar
  38. 38.
    Lüftner D, Grunewald R, Flath B, Akrivakis C, Mergenthaler HG, Blatter J, Possinger K: Gemcitabine with dose escalated epirubicin in advanced breast cancer: Results of a phase I study. Ann Oncol 7(suppl 5): 17, 1996 (abstr)Google Scholar
  39. 39.
    Falkson GF, Gelman R, Falkson CI, Glick J, Harris J: Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: A prospective Eastern Cooperative Oncology Group study. J Clin Oncol 9: 2153-2161, 1991Google Scholar
  40. 40.
    Hohnecker JA: A summary of vinorelbine (navelbine) safety data from North American clinical trials. Semin Oncol 21(suppl 10): 42-47, 1994Google Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Karin Haider
    • 1
  • Gabriela V. Kornek
    • 2
  • Werner Kwasny
    • 1
  • Georg Weinländer
    • 2
  • Julia Valencak
    • 2
  • Friedrich Lang
    • 3
  • F. Püribauer
    • 3
  • Erwin Kovats
    • 4
  • Dieter Depisch
    • 1
  • Werner Scheithauer
    • 2
  1. 1.Department of SurgeryWr. Neustadt General HospitalWr. Neustadt
  2. 2.Division of Oncology, Department of Internal Medicine 1, ViennaUniversity Medical SchoolViennaAustria
  3. 3.Department of SurgeryNeunkirchen General HospitalNeunkirchenAustria
  4. 4.Department of SurgeryBaden General HospitalBadenAustria

Personalised recommendations